Key Points
- Phillip Md Et Al Frost purchased 25,000 shares of Cocrystal Pharma on Dec. 24 at an average price of $0.97, bringing his total stake to 1,728,551 shares (a 1.47% increase) valued at about $1.68 million.
- Across late November and December he made additional insider buys (Nov. 25: 20,000; Nov. 26: 4,000; Dec. 26: 40,000), totaling 89,000 shares acquired in the period.
- Cocrystal Pharma trades around $0.98 with a market cap of roughly $13.5 million, carries negative EPS expectations, and faces mixed analyst views (average rating "Hold" with a $6 target while Weiss Ratings reaffirmed a "sell").
Cocrystal Pharma, Inc. (NASDAQ:COCP - Get Free Report) Director Phillip Md Et Al Frost acquired 25,000 shares of the business's stock in a transaction that occurred on Wednesday, December 24th. The shares were purchased at an average price of $0.97 per share, with a total value of $24,250.00. Following the completion of the acquisition, the director owned 1,728,551 shares of the company's stock, valued at $1,676,694.47. This represents a 1.47% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Phillip Md Et Al Frost also recently made the following trade(s):
- On Friday, December 26th, Phillip Md Et Al Frost purchased 40,000 shares of Cocrystal Pharma stock. The shares were bought at an average price of $0.97 per share, for a total transaction of $38,800.00.
- On Wednesday, November 26th, Phillip Md Et Al Frost purchased 4,000 shares of Cocrystal Pharma stock. The stock was acquired at an average cost of $0.99 per share, for a total transaction of $3,960.00.
- On Tuesday, November 25th, Phillip Md Et Al Frost purchased 20,000 shares of Cocrystal Pharma stock. The stock was bought at an average price of $0.94 per share, for a total transaction of $18,800.00.
Cocrystal Pharma Price Performance
COCP opened at $0.98 on Tuesday. The company has a market capitalization of $13.50 million, a P/E ratio of -1.04 and a beta of 1.04. The firm's fifty day moving average price is $1.03 and its two-hundred day moving average price is $1.32. Cocrystal Pharma, Inc. has a fifty-two week low of $0.90 and a fifty-two week high of $3.26.
Cocrystal Pharma (NASDAQ:COCP - Get Free Report) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.03. On average, equities research analysts expect that Cocrystal Pharma, Inc. will post -1.85 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Cocrystal Pharma in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $6.00.
Check Out Our Latest Stock Analysis on COCP
About Cocrystal Pharma
(
Get Free Report)
Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.
The company's pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
